Heparin Therapy in Pulmonary Embolism

Mechanism and Efficacy

• Heparin provides immediate anticoagulation that prevents further clot formation and extension of existing thrombi, allowing the body's natural fibrinolytic system to gradually dissolve the pulmonary emboli 1, 2
• Heparin should be started immediately when there is high or intermediate clinical suspicion of pulmonary embolism, even before diagnostic confirmation, unless contraindicated 2, 3

Administration Protocol

• Initial treatment typically involves a loading dose of 5,000-10,000 units followed by 400-600 units/kg daily as a continuous infusion 2
• Dosing should be titrated to maintain activated partial thromboplastin time (APTT) at 1.5-2.5 times control values 2
• Weight-based dosing causes fewer APTT fluctuations and achieves therapeutic levels more quickly 1, 2

Treatment Duration and Transition

• Heparin should be continued until adequate maintenance anticoagulation with warfarin is achieved 1, 4
• If continued beyond five days, platelet count must be monitored due to the risk of heparin-induced thrombocytopenia with thrombosis 1, 4
• Warfarin may be started as soon as the diagnosis is confirmed 1, 2

Low-Molecular-Weight Heparin (LMWH) vs. Unfractionated Heparin

• LMWH is at least as effective as unfractionated heparin for treating pulmonary embolism 5, 6
• Current guidelines from the American College of Physicians/American Academy of Family Physicians recommend LMWH over unfractionated heparin for initial inpatient treatment of DVT, while either is appropriate for pulmonary embolism 6, 7

Special Considerations

• In massive pulmonary embolism with hemodynamic instability, thrombolytic therapy may be considered over heparin alone, particularly in the presence of hypotension 1, 8
• Major bleeding is the primary complication of anticoagulation, occurring in approximately 1% of low-risk patients and up to 10% in high-risk patients 4, 8
• Absolute contraindications to heparin include recent hemorrhage, stroke, and current gastrointestinal bleeding 8

Monitoring and Complications

• An unexpectedly poor response to heparin may suggest pre-existing thrombophilia 1, 4
• High-risk patients for bleeding complications include those who have undergone recent surgery, obstetric delivery, or have a history of peptic ulcer disease or bleeding disorders 8

Anticoagulation Therapy for Pulmonary Embolism

Duration and Transition

• The American Thoracic Society recommends that total anticoagulation duration should be at least 3 months for unprovoked pulmonary embolism 9, 10, 11

Special Considerations

• In patients with pulmonary embolism, the presence of concurrent infection, such as possible COVID-19, does not change the initial treatment, and anticoagulation should not be delayed 9, 10, 11
• The absence of right heart strain on CT imaging indicates that thrombolytic therapy is not indicated, and standard therapeutic anticoagulation with heparin is appropriate 9, 10, 11

Contraindications to Assess

• If absolute contraindications to heparin exist, such as active bleeding or recent hemorrhage, consider inferior vena cava (IVC) filter placement instead 9, 10, 11

Indications for Unfractionated Heparin Drip in Pulmonary Embolism

High-Risk Pulmonary Embolism

• The European Society of Cardiology recommends unfractionated heparin (UFH) drip for high-risk pulmonary embolism with hemodynamic instability, as it allows for rapid reversibility and titration to effect 12, 13
• Patients presenting with shock, persistent hypotension, or cardiogenic shock require immediate intravenous UFH, as the risk of delayed treatment outweighs the risk of unnecessary anticoagulation 12, 13

Severe Renal Dysfunction

• The European Society of Cardiology recommends UFH in patients with severe renal dysfunction (creatinine clearance <20-30 mL/min), as it does not accumulate in renal failure and can be safely titrated to effect 12, 13

High Bleeding Risk Requiring Rapid Reversibility

• UFH has a short half-life and can be rapidly reversed with protamine sulfate, making it preferable in patients at elevated bleeding risk 13

Initiation Before Diagnostic Confirmation

• The British Thoracic Society recommends starting anticoagulation with heparin immediately based on clinical suspicion of pulmonary embolism, before imaging confirmation, especially when diagnostic testing cannot be performed within 24 hours 14

Duration and Transition

• The European Society of Cardiology recommends continuing UFH for at least 5 days and until adequate oral anticoagulation (INR 2.0-3.0 for at least 2 consecutive days) is achieved 12, 13